As US Head of Health Economics Analysis, Yang Meng is responsible for the operational and strategic development of the US health economics analysis team and contributes to the leadership for the Modeling & Analytics Practice.
Yang has over 15 years of experience in health modeling spanning academia (including University of Sheffield and University of Warwick) and HEOR consultancy. Yang has led a range of modeling and HEOR projects including HTA submissions/assessments for NICE, US ICER, CADTH/INESSS, SMC, and HTA bodies in Australia, Spain, Italy, France, Belgium, Sweden, Japan and China.
Yang has a core technical skill set covering cost-effectiveness, budget impact, cost-minimization and disease pathway models, model conceptualization, survival modelling, econometrics, patient level data analysis and public health modelling. Yang’s experience in disease areas include oncology (e.g., bladder, prostate, esophageal, gastric, lung, melanoma, non-Hodgkin’s lymphoma, pan-indication), diagnostics of cancers, hepatitis C, mental health, infectious disease and alcohol/addiction.
Yang has published widely in health economics, HTA and alcohol/addiction research in top medical and health economics journals, including Lancet, BMJ, Health Economics, the Journal of Health Economics, and Addiction.
Yang holds a PhD in Healthcare Modeling & Simulation and MSc in Management Science & Operational Research by the University of Warwick, UK.